Merck to still buy Cubist, even after patent setback

[Anonymous]

Another brilliant move by MRK leadership, buying Cubist one day before a federal judge invalidates 4 of its patents. Can we get a rebate? Can we give Cubist back under a "lemon law"? Destined to go in the trash heap of other MRK brilliant acquisitions (Rosetta, Sirna, Schering-Plough, fill-in-the-blanks:______________, _____________, ____________).

=========================================
Merck says still plans Cubist purchase, despite patent setback

Dec 9 (Reuters) - Merck & Co on Tuesday said it will proceed with its planned $8.4 billion purchase of Cubist Pharmaceuticals and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of Cubist's top-selling product.

Merck late on Friday had announced plans to buy Cubist, whose flagship product is the widely used antibiotic Cubicin for skin infections. The deal would give the No. 2 U.S. drugmaker entry into the market for drugs that fight so-called superbugs.

But U.S. District Judge Gregory Sleet in Delaware on Monday invalidated four Cubicin patents and ruled that Hospira Inc can launch a generic version of Cubicin as soon as 2016, two years sooner than Wall Street expectations.

http://finance.yahoo.com/news/merck-says-still-plans-cubist-135952346.html

 

[Anonymous]

Another brilliant move by MRK leadership, buying Cubist one day before a federal judge invalidates 4 of its patents. Can we get a rebate? Can we give Cubist back under a "lemon law"? Destined to go in the trash heap of other MRK brilliant acquisitions (Rosetta, Sirna, Schering-Plough, fill-in-the-blanks:______________, _____________, ____________).

=========================================
Merck says still plans Cubist purchase, despite patent setback

Dec 9 (Reuters) - Merck & Co on Tuesday said it will proceed with its planned $8.4 billion purchase of Cubist Pharmaceuticals and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of Cubist's top-selling product.

Merck late on Friday had announced plans to buy Cubist, whose flagship product is the widely used antibiotic Cubicin for skin infections. The deal would give the No. 2 U.S. drugmaker entry into the market for drugs that fight so-called superbugs.

But U.S. District Judge Gregory Sleet in Delaware on Monday invalidated four Cubicin patents and ruled that Hospira Inc can launch a generic version of Cubicin as soon as 2016, two years sooner than Wall Street expectations.

http://finance.yahoo.com/news/merck-says-still-plans-cubist-135952346.html

While I condone your comment, I disagree with your premise. Kenny has native primordial understanding as to what Merck needs as the reorganization moves forward.

 

[Anonymous]

A fool and his money are soon parted!

 

[Anonymous]

LOL! Awesome job Merck. Please tell me someone got fired over this.

You bought a generic drug, three dogs, and an inferior gram negative. The entire sales force at Cubist left for a reason over the last few months.

Cubist management is so damn smart! Hat tip to them!

 

[Anonymous]

A fool and his money are soon parted!

Another short sited blunder by Merck. Maybe Kenny will try to take on this patent fight himself...sort of like the Vioxx situation.

 

[Anonymous]

Another short sited blunder by Merck. Maybe Kenny will try to take on this patent fight himself...sort of like the Vioxx situation.

Now you know why Merck will have to layoff more employees. They pay a band drug premium price for a me too generic company....

Way not to go........

You can't make this stuff up.

Maybe they will now back out of this deal. Does not look good. Better to cut your loses while you are ahead. This is a very bad move.

 

[Anonymous]

This article really exposes the MRK stupidity...

http://blogs.wsj.com/pharmalot/2014...-do-now-that-cubist-lost-a-key-patent-ruling/

 

[Anonymous]

While I condone your comment, I disagree with your premise. Kenny has native primordial understanding as to what Merck needs as the reorganization moves forward.

Your spellcheck made some mistakes... I'm sure you meant "naive prima donna understanding"...
;-)

 

[Anonymous]

What makes for sense...
Buying CEMP, TTPH and DRTX for a combined 2.5 billion or Cubist for 9.2? Hell if its pipeline you want why not buy CTIX as well! Idiots!

 

[Anonymous]

Ken is a solid performer who will shape Merck into a strong company!

 

[Anonymous]

What makes for sense...
Buying CEMP, TTPH and DRTX for a combined 2.5 billion or Cubist for 9.2? Hell if its pipeline you want why not buy CTIX as well! Idiots!

We are not done buying. We still have money and will not throw it into our crappy R&D department. I am sure there is a reason why we overpaid. Where is cubist? I know we are doing everything to get out of NJ.

 

[Anonymous]

I didn't know fred Hassan was at cubist. Nice job Fred.

 

[Anonymous]

The title of the news story should be...

Merck management gets it in the ass again!

 

[Anonymous]

Ken is a solid performer who will shape Merck into a strong company!

Best joke I heard all year. This was a joke, right?

Saying that Merck has gone to the dogs is an insult to dogs!

 

[Anonymous]

The title of the news story should be...

Merck management gets it in the ass again!

Merck management never even gets a finger in the ass. They make the decisions and the employees get the high hard one.

 

[Anonymous]

Another short sited blunder by Merck. Maybe Kenny will try to take on this patent fight himself...sort of like the Vioxx situation.

Ironic, even you can stumble onto the right answer. The case will be appealed for years and revenue will continue. If big Ken beat the Vioxx misstep this will a walk in the park!

 

[Anonymous]

What's overpaying $2 or $3 Billion to Merck? They will just fire more people.

 

[Anonymous]

What's overpaying $2 or $3 Billion to Merck? They will just fire more people.

Honestly, what is a billion or two, as long as you don't own that stock.

 

[Anonymous]

LOL! Awesome job Merck. Please tell me someone got fired over this.

You bought a generic drug, three dogs, and an inferior gram negative. The entire sales force at Cubist left for a reason over the last few months.

Cubist management is so damn smart! Hat tip to them!

The B-school mastermind at Merck who orchestrated this deal didbn't get fired, but got a promotion, huge salary increase, and special achievement award. Probably one of the arrogant MMAs who do a 6 month rotation in a variety of departments and think they are the expert on everything. Trouble with these guys is that their arrogance (and true lack of knowledge and expertise) blinds them from due diligence - Schering, Rosetta, Inspire (Zioptan anyone?), etc, etc, etc. the list goes on...
Obviously, there must be something us mere mortals are missing

 

[Anonymous]

Merck knew this long before the acquisition.Reps aren't paid to to think on matters complex as these, so just deliver lunches and free product get a quick face to face or sig once a week and then bitch about something you know nothing about. Ken will steer us to victory no doubt ! If you lose your position in the course of events, then too bad !